Vanguard Group
LIMN

Vanguard Group’s Liminatus Pharma LIMN Stock Holding History

Vanguard Group’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$44.8K Hold
73,424
– – ﹤0.01% 4255
2025
Q3 		$123K Hold
73,424
– – ﹤0.01% 4202
2025
Q2 		$819K Buy
+73,424
New +$824K ﹤0.01% 3796

Other funds holding LIMN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Vanguard Group's LIMN Position: Q4 2025 in Review

Vanguard Group held its Liminatus Pharma (LIMN) position steady in Q4 2025 at 73,424 shares worth $44.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4255.

Vanguard Group first reported a position in LIMN in Q2 2025 and has held it in 3 quarters since. The position peaked at $819K in Q2 2025. 12 funds tracked by Wall St. Rank hold LIMN as of Q4 2025.

  • Vanguard Group held 73,424 shares of Liminatus Pharma worth $44.8K as of Q4 2025.
  • Vanguard Group left its Liminatus Pharma share count unchanged in Q4 2025.
  • Liminatus Pharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4255 holding.
  • Vanguard Group first reported a position in Liminatus Pharma in Q2 2025 and has held it in 3 quarters since.
  • Vanguard Group's Liminatus Pharma position peaked at $819K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held Liminatus Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.